APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 35 people and is led by a management team with strong background in drug development, especially in immuno-oncology.


Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and its first application for marketing authorization is under review.
See projects for the present status of Apeiron's portfolio.

 

  • 821 hits04 October 2016

    APEIRON Grants EUSA Pharma Global Rights to Immunotherapy

    APEIRON Biologics AG grants EUSA Pharma, UK exclusive global commercialization rights to the oncology product ISQETTE®. ISQETTE® is an antibody-based immunotherapy with orphan drug designation for the treatment of pediatric neuroblastoma. The therapy has been developed by APEIRON together with an academic network including the St. Anna Children's Cancer Research Institute in Vienna.

     Presseaussendung

     Press Release